Immunotherapy before targeted therapy extends OS in metastatic melanoma

Posted in Cancer Cell Biology Program News

November 16, 2021 – Patients with BRAF V600 mutation-positive metastatic melanoma who received an immune checkpoint inhibitor combination followed by targeted therapy survived longer than those who received the reverse sequence, according to study findings.

Results of the randomized phase 3 DREAMseq trial — presented during the inaugural ASCO Plenary Series — challenge existing treatment standards.